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Clinical observations reveal that an augmented pace of T-cell recovery after chemotherapy correlates with
improved tumor-free survival, suggesting the add-back of T cells after chemotherapy may improve
outcomes. To evaluate adoptive immunotherapy treatment for B-lineage non-Hodgkin lymphoma (NHL),
we expanded T cells from client-owned canines diagnosed with NHL on artificial antigen presenting cells
(aAPC) in the presence of human interleukin (IL)-2 and IL-21. Graded doses of autologous T cells were
infused after CHOP chemotherapy and persisted for 49 days, homed to tumor, and significantly improved
survival. Serum thymidine kinase changes predicted T-cell engraftment, while anti-tumor effects correlated
with neutrophil-to-lymphocyte ratios and granzyme B expression in manufactured T cells. Therefore,
chemotherapy can be used to modulate infused T-cell responses to enhance anti-tumor effects. The
companion canine model has translational implications for human immunotherapy which can be readily
exploited since clinical-grade canine and human T cells are propagated using identical approaches.
C
hemotherapy employed for cytoreductive effects can be harnessed to modulate tumors and their micro-
environment to present neo-antigens1–4. However, the cellular immune response to tumor-associated
antigens (TAA) is compromised after chemotherapy due to iatrogenic lymphodepletion. This prompted
us to test the hypothesis that add-back of autologous polyclonal T cells after chemotherapy can result in improved
immune-mediated anti-tumor responses. This is supported by observations that improved recovery of T-cell
numbers after lymphodepleting chemotherapy is predictive of tumor-free survival in patients with colorectal
cancer, non-small cell lung carcinoma, cervical tumor, and non-Hodgkin lymphoma (NHL)5–10. To generate
clinically-sufficient numbers of T cells for adoptive transfer, we and others have developed culturing platforms
based on artificial antigen presenting cells (aAPC)11–15. To assess whether infusions of non-specific T cells
propagated ex vivo on aAPC improve survival after standard-of-care chemotherapy, we developed the compan-
ion canine as an out-bred large animal cancer model for immunotherapy of spontaneously-occurring NHL.
Cancer in client-owned dogs models human malignancies due to their genetic similarity, large size, spontan-
eous occurrence of a broad diversity of tumor types, and similar treatment modalities16,17. The etiology of
spontaneous canine and human cancers is analogous as both arise from genetic abnormalities or predisposition
and common environmental exposures. NHL is the most common canine malignancy accounting for up to 24%
of all reported neoplasms18,19. Similar to humans, the majority of canine NHL (60–80%) arises from malignant B
cells. The most common presentation is a generalized lymphadenopathy corresponding to stage IV to V disease,
with stage V describing tumor in blood, bone marrow, and other organ systems. The current standard-of-care
treatment for canine B-lineage NHL is the combination chemotherapy regimen of cyclophosphamide, vincris-
tine, doxorubicin, and prednisone (CHOP), which induces a temporary remission in approximately 85% of
canines, but is rarely curable as the two-year survival rate is less than 20%20. Although other chemotherapy
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regimens have been compared to CHOP, none have significantly
improved the overall survival of canines with NHL20.
In the present study, we report that clinically-sufficient numbers
of T cells can be expanded from the peripheral blood (PB) of all 8
treated out-bred canines with spontaneous NHL, using K562 cells
genetically modified to function as aAPC. Non-specific autologous
ex vivo-propagated T cells were noted to persist after infusion, traffic
to secondary lymphoid tissue, and improve the survival of canines
receiving CHOP for spontaneously-occurring B-lineage NHL, com-
pared to control dogs matched for disease stage and remission status
which received only CHOP. The therapeutic potential of T-cell ther-
apy is dependent on peristence, homing, and effector functions.
Biomarkers were developed to report on some of these variables.
T-cell engraftment correlated with thymidine kinase (TK) serum
levels while decreased neutrophil-to-lymphocyte ratios (NLR) cor-
related with an improved anti-tumor effect. T-cell effector function
was augmented after ex vivo propagation as supported by changes in
mRNA profiles and an improvement in canine survival that corre-
lated with up-regulated T-cell expression of granzyme B. In sum-
mary, T-cell therapy in out-bred companion canines with cancer is
justified not only to improve their survival, but as a model that
informs on human immunotherapy of NHL.
Results
Immunophenotype of PB-derived T cells. Flow cytometry, anal-
yzed in a lymphocyte gate, was used to reveal protein expression
on T cells derived from PB obtained from healthy subjects and
canines diagnosed with NHL before their treatment with CHOP
(Figure (Fig) 1). In healthy dogs the average CD31 population was
746 4% (mean6 s.e.m.) with CD31CD41 T cells (336 3%)making
up a reduced percentage of the overall T-cell population compared to
CD31CD81 T cells (54 6 6%). Among the CD31CD41 population,
1.2 6 0.03% co-expressed CD25 which is consistent with a low
number of circulating numbers of regulatory T cells (Tregs).
Natural killer (NK) cells, described as CD3negCD561, comprised an
average of 11 6 6%, while CD3negCD211 B cells were present at 17 6
3%. In comparison (Fig 1), the percentage of CD31 T cells in the PB
obtained from canines with NHL (30 6 8%) was lower (p 5 0.003).
Similarly, the NK-cell (0.2 6 0.05%) and B-cell populations (4.1 6
1.3%) were also decreased (p5 0.13 and p5 0.008, respectively). We
noted that PB from canines withNHLhad an increased percentage of
CD31CD41 T cells (21 6 6%) and a decreased percentage
CD31CD81 T cells (9 6 4%) which resulted in an ‘‘inverted ratio’’
compared to healthy donors. The difference in percentage of
CD31CD81 T cells between healthy subjects and canines with
NHL was statistically significant (p 5 0.0006). A slight rise in the
CD41CD251 population (4 6 3%, p 5 0.18), presumably reflects an
increased number of Tregs, in canines withNHL, compared to healthy
subjects and is consistent with a state of immunosuppression. As a
marker for both the potential of T cells to migrate to lymph node
(LN) and memory phenotype21, we noted that the CD31CCR71 T
cells in PB from healthy subjects was 9 6 3%, but was reduced to 0.8
6 0.6% in PB of canines with NHL (p 5 0.04).
Canine T cells can be non-specifically and efficiently propagated
on aAPC when co-cultured with IL-21. Canine T cells from the PB
of healthy subjects were numerically expanded on c-irradiated aAPC
Figure 1 | Composition of circulating canine T cells. The expression of T-cell subsets in PB from (a) healthy subjects (n 5 4) and (b) canines with NHL
(n5 4) prior to CHOP treatment. Percentage expression is based on cells within a lymphocyte gate described by a Forward vs. Side Scatter flow cytometry
plot. Mean 6 s.e.m. are shown.
www.nature.com/scientificreports
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CLN4, pre-loaded via CD64 with OKT3 to cross-link canine CD3,
and human recombinant (rh)IL-2 and rhIL-21 (Fig 2A). The
homology between human and canine IL-2, IL-15, and IL-21 is
shown in Supplementary Table S1. T cells propagated in the
presence of graded doses of rhIL-2 had limited replicative
potential, for while the T cells remained viable over a 35-day
culturing period, they demonstrated only a 6.5 6 2.4 fold
expansion (n 5 2). Therefore, we determined whether supple-
mental signaling through the common c-cytokine receptor could
augment canine T-cell proliferation. The addition of graded doses
of rhIL-21 in addition to rhIL-2 maintained T-cell viability (Fig 2C)
and resulted in 3996 124 fold expansion over 35 days (3136 75 fold
expansion after 28 days; n 5 2, p 5 0.03) which was greater than the
numeric expansion achieved with only rhIL-2 (Fig 2B).We observed
that the largest numbers of T cells were produced at the highest
concentration of rhIL-21 (Fig 2B). These data demonstrate that a
combination of exogenous rhIL-21 and rhIL-2 in coordination with
cross-linking CD3 via OKT3 are required to sustain proliferation of
canine T cells on CLN4 aAPC.
rhIL-21 selectively propagates canine CD81T cells.The addition of
rhIL-21 selectively propagates human CD81 T cells22 which is
desirable as the cytolytic effector function of infused CD81 T cells
can control tumor growth23. We therefore investigated the influence
of rhIL-21 in combination with rhIL-2 to selectively propagate CD81
versus CD41 canine T cells.We observed a decrease in the expression
of CD31CD81 T cells from 76 6 1% on day 7 to 14 6 3% on day 35
when T cells were cultured on CLN4 with rhIL-2, whereas the
expression of CD31CD81 T cells cultured with both rhIL-2 and
rhIL-21 increased from 73 6 2% on day 7 to 95 6 2% on day 35
(Fig 2D). These data are consistent with the ability of rhIL-21 to
preferentially support outgrowth of canine CD81 T cells which has
practical implications for following the fate of infused T cells, as
canines with NHL have inverted ratio of CD4:CD8 (Fig 1) and
after CHOP preferentially recover CD41 T cells.
Propagation of T cells from canines with B-lineage NHL. Late
stage presentation of NHL and treatment with CHOP leads to T-
cell lymphopenia characterized by decreased numbers of CD31 T
cells and low numbers of CD81 T cells, similar to observations in
humans after CHOP (Fig 1)24. The culture conditions established to
selectively expand CD81 T cells from healthy dogs were applied to
numerically expand T cells from canines with NHL. After 28 days of
co-culture on CLN4 and rhIL-21/2, T cells underwent an average 124
6 44 fold expansion (n 5 6) which was less than achieved using T
cells fromhealthy subjects (2216 39 fold expansion, p5 0.04, n5 6)
and is likely indicative of an initial partial defect in T cells from
canines with NHL to be fully activated for proliferation (Fig 2F).
Even so, the aAPC-based expansion methodology was sufficient to
achieve the T-cell numbers necessary for adoptive immunotherapy.
These data demonstrate that the platform technology of every 7-day
additions of c-irradiated aAPC in combination with rhIL-2 and
rhIL-21 can sustain the proliferation of T cells and provides the
foundation for infusing ex vivo-propagated autologous T cells in
canines diagnosed with advanced-stage NHL.
Characterization of propagated T cells used for adoptive transfer.
PB-derived T cells from enrolled canines (Supplementary Fig S1 and
S2) with NHL recursively stimulated on c-irradiated CLN4 in the
presence of rhIL-2 and rhIL-21 for up to 35 days of culture
underwent a mean 109 6 15 fold expansion (Fig 3A). Seven days
after the first aAPC-mediated stimulation the cultures contained T
cells that were: 89 6 6% CD31, 60 6 8% CD31CD81, and 27 6 8%
CD31CD41. By day 14, cultures were predominantly CD31CD81
(90 6 4%) and the mean CD31CD41 population had decreased to
8 6 4% (Fig 3B). T-cell infusion products analyzed for 6 (of the 8)
treated dogs at the time of their cryopreservation were on average
(Fig 3C): 98 6 1% CD31; 88 6 2% CD31CD81; 11 6 3%
CD31CD41; 0.2 6 0.2% CD3negCD211 (B cells); 73 6 10%
CD31CCR71 (central memory); and 90 6 2% PKH-261
(fluorescence label to track persistence). To evaluate a T-cell
effector function (n 5 3) we assessed the IFN-c production upon
cross-linking CD3 with OKT3 loaded on CLN4 (Fig 3D). All the
propagated CD31CD81 T cells, in contrast to the few numerically
expanded CD31CD41 T cells, generated IFN-c (99.16 1% versus 3.7
6 0.6%). It was noted that of the propagated CD41 T cells, 8 6 3%
co-expressed CD25 and their reduced production of IFN-c is
consistent with a regulatory function. The selective propagation of
CD81 T cells that could be activated to secrete IFN-c was exploited
for adoptive immunotherapy.
T-cell gene expression. T cells from canines with NHL exhibited a
decreased in vitro proliferative potential on aAPC consistent with T-
cell dysfunction. Therefore, we investigated whether the propagation
process could produce T cells that were genetically similar to T cells
from healthy donors. This was undertaken by multiplex digital
profiling using the nCounter analysis system to quantify a panel of
selected genes (Supplementary Table S2). The detected mRNA
species undergoing a significant change (p,0.001, fold-change
.2) were identified in T cells from healthy subjects and patients
with NHL by comparing pre-expansion with post-expansion
samples and then filtering for uniformity. After propagation for 28
days, 40mRNA species were up-regulated in at least 5/6 canines with
NHL as well as in T cells from healthy subjects (Fig 3E). Similarly,
we noted a set of 83 mRNA species that decreased (p,0.001, fold-
change ,2) after expansion in at least 5/6 canines with NHL and
healthy subjects (Fig 3F). Gene products associated with T-cell
cytoxicity (granzymes, IFN-c, perforin), proliferation (EOMES,
DPP4, TNFRSF9, LCK, ZAP70), and trafficking to LN and
inflammation (CCL3, CCL4, CCL5 receptors) were up-regulated
after propagation. Similarly, mRNA species coding for both IL-2
and IL-21 receptors were increased reflecting the use of rhIL-2 and
rhIL-21 during the propagation process. mRNA species coding for
FOXP3 were significantly decreased in the infusion product,
corresponding to the decreased number of Treg produced during
expansion. In aggregate, the synchronous direct quantification of
multiple mRNA species revealed a pattern of gene expression that
was similar whether the T cells were propagated from healthy dogs or
canines with NHL.
Adoptive transfer of propagated T cells. The ratio of CD4:CD8 T
cells in PB was serially assessed as a measure of persistence of infused
predominately CD81 T cells (Fig 4A). The CD4:CD8 ratio in healthy
subjects was 1.6516 0.2 (n5 4) while themean pre-infusion ratio in
canines with NHL was 351. After each infusion (predominately
containing CD81 T cells), the average ratio decreased to 151.2
after the third dose (n 5 6), which was significantly reduced
compared to pre-infusion measurements (p 5 0.05). We also
observed that the percentage of CD31CD81 T cells in PB increased
after each T-cell infusion. The mean number of CD31CD41 and
CD31CD81 T cells pre-infusion was 585 6 223 cells/mL and 188
6 44 cells/mL, respectively. By study day 35, the mean CD31CD41
andCD31CD81 T-cell counts in PBwere 3056 166 cells/mL and 469
6 142 cells/mL, respectively. Similarly, the mean absolute
lymphocyte count (ALC) increased after the T-cell infusions
(Supplementary Table S3) which reflected an increase (from 64%
to 79%) in CD31 T cells above pre-infusion levels over the same 35
day time frame (Fig 4B). To directly examine the persistence of
adoptively transferred T cells, the infusion products were pre-
labeled with PKH-26, a red fluorescent dye. PKH-261CD31 T cells
incrementally increased in the PB after each of the three graded T-cell
infusions and were detectable for up to 49 days (Fig 4C). Toxicities
attributed to T cells were confined within a 72-hour period after the
second T-cell infusion with the majority of the seven recorded
www.nature.com/scientificreports
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Figure 2 | rhIL-21 preferentially propagates canine CD81T cells on OKT3-loaded aAPC. T cells isolated from PBMC of healthy dogs were numerically
expanded on c-irradiated OKT3-loaded aAPC at a T-cell : aAPC ratio of 251. T cells were re-stimulated with aAPC every 7 days. Recombinant human IL-
21 and/or rhIL-2 were added to the co-culture of T cells on aAPC as shown. (a) Parental K562 cells were genetically modified to co-express human CD64
and the human T-cell co-stimulatory molecules CD86, CD137L, andmembrane-bound IL-15 (co-expressed with EGFP) and cloned (CLN4). OKT3 was
loaded via introduced CD64 on CLN4 and detected with a Fab-specific antibody. CLN4 is shown as gray-open histograms and K562 parental cells as
black-open histograms. (b)Numeric expansion of T cells on c-irradiatedOKT3-loaded aAPC (added every 7 days) in the presence of rhIL-2, or both rhIL-
2 and rhIL-21. The average cell counts from two donors are shown. (c) The mean viability of T cells during co-culture on aAPC and cytokine(s) (n 5 2).
Percentage expression (n52) of (d) CD31CD81 and (e) CD31CD41T cells upon co-culture with aAPC and cytokines(s). (f) Numeric expansion of T cells
measured over culture time on aAPC and rhIL-2 and 21 recorded as themean inferred cell count (black dashed line) based on 5 healthy subjects (blue solid
line) and 5 non-trial canines with NHL (orange solid line). Upward arrows indicate timing for the addition of c-irradiated OKT3-loaded aAPC.
www.nature.com/scientificreports
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adverse events being Grade I or II (Table 2). One canine with a Grade
III gastrointestinal adverse event required hospitalization for
dehydration (24 hours). In aggregate, these data support that
multiple doses of ex vivo propagated T cells can be safely admini-
stered to canines with NHL and persist after infusion.
Adoptively transferred T cells migrate to tumor. Ten days after the
last infusion, enlarged LNs were sampled to determine if the
administered T cells migrated to sites of tumor. Under fluorescent
microscopy, PKH-261 T cells could be detected throughout a LN and
this was concordant with the expression of CD3 (Fig 4D). Thus, we
conclude that the infused T cells can traffick to, and persist in,
secondary lymphoid tissue containing tumor.
Adoptive transfer of T cells after CHOP improves survival. To
evaluate the ability of ex vivo-propagated T cells to impact canine
survival, we compared the 8 dogs that received CHOP and auto-
logous T cells with a cohort of stage-matched canines with NHL
that received only CHOP. Both cohorts were followed for 500 days
post initial diagnosis of NHL or obtaining CR for the analysis of
tumor-free survival. As expected, 7 of 8 dogs that received T-cell
infusions achieved a prior complete remission (CR) from CHOP.
However, we observed that the infusion of T cells after CHOP
resulted in marked improvements in overall and tumor-free
survival and that this was evident when only 8 dogs had been
infused (Fig 5). The historical controls which were matched for
age, size, disease stage, and achieving CR after CHOP with the
canines that received T cells after CHOP. This control population
had a median overall survival (n 5 12) of 167 days (range from 68 to
413 days) upon initial diagnosis of NHL and a median tumor-free
survival (n5 12) of 71 days (range from 23 to 293 days) following the
CR achieved after receiving CHOP. Significantly, for the 8 canines
receiving CHOP combined with T-cell infusions the median overall
survival was improved to 392 days (range 277 to 458 days) and the
tumor-free survival improved to 338 days (range 104 to 369 days).
The hazard ratio and p-value for the log rank test of overall survival
were 4.3 and 0.03, respectively. T-cell infusions significantly
increased the period of tumor-free survival when used in
conjunction with CHOP therapy (p 5 0.005) which implies a
clinical benefit to dogs with NHL that received immunotherapy.
Biomarkers. The therapeutic potential of the infused T cells is
dependent in part on their persistence and their effector function.
TK is elevated during DNA synthesis25 and we tested whether TK
could be used tomonitor proliferation and survival of infused T cells.
To determine whether TK was secreted by proliferating T cells, T
cells were co-cultured for 48 hours with c-irradiated OKT3-loaded
CLN4 and cytokines which resulted in elevated TK levels (28.6 6
2.5 U/L) in the conditioned supernatant compared to c-irradiated T
cells (p5 0.03) andT cells co-culturedwith cytokines only (p5 0.04)
(Supplementary Figure S3). Therefore, using TK as a biomarker for
proliferation, we observed that serum TK levels (Fig 6A) were
Figure 3 | Characterization of T-cell infusion products. (a) Themean inferred cell count for 6 (of the 8) canines infusedwith T cells that were propagated
over 28–35 days on c-irradiated OKT3-loaded aAPC (CLN4) in presence of rhIL-2/IL-21. Arrows represent days aAPC were added. (b) Percent
expression of CD41 and CD81 T-cell subsets during propagation on c-irradiated aAPC in the presence of rhIL-2/IL-21. Arrows represent days aAPCwere
added. (c) Immunophenotype of the T-cell infusion products (n 5 6) at the time of cryopreservation. The horizontal lines describe mean percentage
expression. (d) T-cell infusion products were tested for IFN-c production after stimulationwithOKT3-loaded aAPC in the presence of rhIL-2/IL-21 (n5
3). Analysis of multiplexed digital gene profiling of PB-derived canine T cells before and after propagation from healthy subjects (n5 2) and canines with
NHL (n 5 6) identified mRNA species which were either significantly (p,0.001) (e) up-regulated (. 2 fold change) or (f) down-regulated (, 2 fold
change) in both healthy subjects and in at least 5 of 6 canines with NHL. (g) Study design: Enrollment occurred pre-, post, or during treatment with
CHOP. Enrolled canines received one course of CHOP, typically administered over 19 weeks, and received one to three infusions of T cells 14 days apart
using an intra-patient dose-escalation scheme.
www.nature.com/scientificreports
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Figure 4 | Tracking infused T cells. (a) Ratio of CD4:CD8 T cells in PB after CHOP, but before adoptive transfer of T cells and compared with
measurements taken three hours after each T-cell infusion. The grey shaded area represents the mean CD4:CD8 ratio (1.651) in healthy subjects (n 5 4).
(b) Mean T-cell counts in PB from 6 canines before and after adoptive transfer of T cells. The grey shaded area represents the range for CD81 T cells in
healthy subjects (n 5 4, 581 to 958 cells/mL). Arrows represent days T cells were infused. (c) Mean expression of CD31 T cells pre-stained with red
fluorescent dye, PKH-26, in the PB of 6 canines. Arrows represent days T cells were infused. (d) Evaluation of fluorescence and staining of CD3 from a LN
biopsy. Frozen tissues were viewed with fluorescent microscopy to detect (top) PKH-261 (red) T cells and (bottom) co-stained with anti-CD3 (black) to
validate T-cell presence.
www.nature.com/scientificreports
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elevated for 4 weeks after the T-cell infusions and appeared to track
with the presence of adoptively transferred T cells (study day 14
average: 24.8 6 8.3 U/L and study day 28 average: 49.2 6 18.5 U/
L, n5 5). Serum fromhealthy canines (n5 2) revealed that themean
TK concentration was 5.8 6 1.8 U/L. These studies indicate that TK
may be a biomarker for the presence of infused T cells which
presumably propagate after adoptive transfer.
To investigate the impact of T-cell persistence on canine survival,
we measured the NLR, recognizing that the absolute neutrophil
count (ANC) is one measurement of hematopoietic recovery after
CHOP chemotherapy and thus can serve as a marker for T cells
arising from bone marrow reserves versus adoptively transferred.
We noted that the NLR decreased (p 5 0.04) in patients which
experienced a prolonged remission (Fig 6B). The pre-infusion
NLR for patients sustaining remissionwas 6516 1.2 and it decreased
significantly to 2.251 6 .5 by study day 35 (p 5 0.03). The pre-
infusion NLR in canines with an abbreviated remission (including
the patient P42 with stable disease) was 6.751 6 3.2 and increased to
35.851 6 30.4 at study day 35. Excluding P42, the NLR at study day
35 was 5.751 6 2. Thus, a decreased NLR ratio may be predictive of
improved canine survival. We measured granzyme B as a marker for
T-cell effector function and observed that its expression in the infu-
sion product correlated with improved tumor-free survival (Fig 6C).
In patients with decreased (# 118 days) tumor-free survival (or
stable disease), only 28 6 7% of the propagated T cells expressed
granzyme B, compared to 996 0.5% of T cells infused in canines who
sustained a remission for longer than 119 days. The correlation
between the tumor-free survival and increased percentage of propa-
gated T cells expressing granzyme B was statistically significant (p 5
0.0018). These data demonstrate that inspection of the T-cell product
may be used to stratify patients at risk for progression of NHL. In
summary, both a decreased NLR and an increased expression of
granzyme B were associated with improved outcome for canine
NHL patients treated with CHOP and T cells.
Discussion
Autologous CD81 T cells expressing T-cell receptors with undefined
specificities (non-specific) were numerically expanded on c-
Figure 5 | Adoptive transfer of ex vivo propagated T cells after CHOP improves survival of canines with NHL. Differences between 12 historical stage-,
age-, and size-matched controls treated with CHOP (red dashed line) and 7 (curve A) or 8 (curve B) research participants treated with CHOP and T cells
(blue solid line) over 500 days in evaluating (a) tumor-free survival measured after achieving CR (p 5 0.005) and (b) overall survival measured upon
diagnosis of NHL diagnosis (p 5 0.03). One dog (P42) had progressive disease at the time of T-cell infusions and was not evaluated in the tumor-free
survival analysis, but was included in the overall survival analysis. This patient had stable disease for 112 days after study day 14.
www.nature.com/scientificreports
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Figure 6 | Biomarkers that inform on T-cell engraftment and canine survival. (a) Serum TK concentration in canines (n 5 5) plotted with the number
of CD31CD81 T cells in PB. Arrows indicate the infusion of T cells. (b) NLR on study day 35 plotted as a function of tumor-free survival. Horizontal
arrow indicates NLR in PB of healthy canines. (c) Expression of granzyme B in propagated T cells, assessed at time of cryopreservation, plotted as a
function of tumor-free survival.
www.nature.com/scientificreports
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irradiated OKT3-loaded aAPC in presence of human cytokines and
infused into canines with advanced NHL to achieve improved anti-
tumor effects after CHOP chemotherapy. The adoptively transferred
T cells were able to persist for at least 49 days in the PB, based on the
measurement of a fluorescent tag, and traffic to sites of disease.
Digital profiling showed that the genetic signature of propagated
mostly CD81 T cells was similar between healthy dogs and canines
with NHL. Elevated serum TK levels correlated with persistence and
propagation of adoptively transferred T cells. A decreased NLR and
increased T-cell expression of granzyme B were predictive of positive
outcomes for canines with NHL. These data provide a foundation for
further improving the potency of T-cell infusions through the
enforced expression of a chimeric antigen receptor to redirect spe-
cificity for a lineage-specific antigen on canine malignant B cells.
Cancer in companion canines is a comparative model for human
malignancies that has advantages compared to murine studies evalu-
ating adoptive T-cell therapies. Previous immunotherapies in out-
bred canines included mAbs, vaccines, and hematopoietic stem-cell
transplantation26,27. The large companion dog population and wide-
spread prevalence of canine cancers can power pre-clinical human
trials to determine feasibility, efficacy, and safety in order to expand
our knowledge of applied cellular therapy28.
The approach to propagating canine T cells mirrors our current
methodology to numerically expanding human T cells as both
employ recursive additions of the same aAPC, rhIL-2 and rhIL-21.
Currently, for our human trial to treat advanced CD191 lymphoid
malignancies (clinicaltrials.gov identifier: NCT00968760), we prop-
agate clinical-grade genetically modified human T cells on these
same aAPC (CLN4) in the presence of similar concentrations of
soluble rhIL-2 and rhIL-21. The use of aAPC for the canine trial
resulted in the robust and preferential outgrowth of CD81 T cells.
Indeed, rhIL-21 in conjunction with rhIL-2 has been shown tomain-
tain the T-cell expression of CD28 and enhance survival, prolifera-
tion, antigen affinity, and production of cytokines after antigen
stimulation8,22,29–34. Of significance to our study, CD81 T cells treated
with rhIL-21 demonstrated increased transcription of genes related
to LN homing and cytolytic effector function35.
The approaches to improve propagation of T cells in vitro can be
combined with manipulation of the recipient to improve T-cell ther-
apy. Add-back of T cells in the lymphopenic recipient augments
adoptive immunotherapy by decreasing undesired regulatory or sup-
pressor cells, elevating cytokines that promote engraftment and
modulating the tumor microenvironment. Indeed, chemotherapy
that induces lymphopenia may increase the expression of neo-
antigens by residual tumor3,36–38. Chemotherapy has been previously
used as an immune-modulating agent to generate mAbs specific for
TAA39 and one explanation for the clinical benefit of the add-back of
the propagated T cells in our canine study is that treatment with
CHOP resulted in the presentation of TAAs that could be recognized
by the infused polyclonal population of T cells2,4.
Augmented recovery of T-cell numbers after chemotherapy has
been previously noted to correlate with improved rates of malignant
relapse and decreased mortality23. Indeed, longitudinal measure-
ments of ALC can predict improved survival in patients with solid
tumors and hematological malignancies7,9,40. Adoptive immunother-
apy trials are underway in human patients that may inform on the
ability of T cells that have been non-specifically propagated ex vivo
to provide anti-tumor responses. It was observed that the number
of CD31CD81 T cells tended to remain elevated in those canine
patients that achieved a CR which is also supportive of a T-cell
mediated anti-tumor effect. Recovery of T-cell subsets may also
impact the anti-tumor responses. An increased CD4:CD8 ratio has
been shown in humans to be an indicator of decreased response to
chemotherapy and poor prognosis41,42. We note that in our canine
trial, the adoptive transfer of CD81 T cells was able to normalize the
inverted CD4:CD8 ratio assessed pre-infusion. Measuring the recov-
ery of T-cell counts in PB raises the question whether T cells can
home to sites of malignant disease as the presence of tumor-infilt-
rating human CD81 T cells correlates with improved tumor control
and prognosis10,43–45. Digital profiling revealed that the propagated
canine T cells up-regulated mRNA species coding for desired che-
mokines receptors for CCL3, CCL4 and CCL5, which is consistent
with the ability to home to LNs. This was supported by observation
that infused CD81 T cells demonstrated a capacity to traffick to
tumor as they were detected inside LNs containing tumor 10 days
post infusion.
In addition to measuring that ability of T cells to home to sites of
malignant disease, we investigated biomarkers that inform on T-cell
persistence and their cytolytic potential and thus could impact the
therapeutic potential of adoptive immunotherapy. Serum TK is a
prognostic factor in several human cancers, including NHL and
canine malignancies25,46,47 and transient increases in serum TK levels
occur after chemotherapy, surgery, inflammation, and infection48.
We demonstrate that TK levels also correlated with in vitro propaga-
tion and in vivo persistence of infused T cells. An increased NLR has
been shown to be a negative prognostic factor in human cancers,
including NHL49–51 and we report that a decreased NLR correlated
with improved canine tumor control. In addition to T-cell numbers,
we examined the potential effector function of the infused product
and demonstrated that an elevated T-cell expression of granzyme B
correlated with improved control of NHL.
In summary, we demonstrate that the companion canine is an
informative comparative oncology model regarding clinical benefits
for adoptive transfer of propagated non-specific T cells after CHOP.
The augmented tumor-free survival after canine T-cell therapy is
reminiscent of the improved survival observed in humans that received
CD20-specific therapeutic mAbs when combined with CHOP52–54.
Our data suggest that chemotherapy can be used as an immune-modu-
lating agent and that add-back of canine or human T cells after chemo-
therapy may be an approach to improving tumor-free survival, which
has implications for NHL, as well as other tumor types.
Methods
Eligibility for clinical trial. Client-owned canines treated at Texas A&M University
(TAMU) College of Veterinary Medicine participated with owner’s written consent.
A diagnosis of stage IV or V B-cell lineage NHL encompassed the inclusion criterion,
while the exclusion criterion included: canines too ill to proceed, allergies to bovine or
murine products, and insufficient T-cell ex vivo expansion. Ten canines were enrolled
and 8 infused with autologous ex vivo-propagated T cells. Before adoptive immu-
notherapy, one patient died unrelated to NHL or chemotherapy and the other was
lost. Enrolled patients were monitored for up to 500 days post NHL diagnosis and
actively monitored after the first T-cell infusion.
Study Design. Upon enrollment (2009–2010), fine needle aspirates (FNA) of LNs
verified B-lineage NHL (Supplementary Fig S1). Trial participants are described in
Table 1, Supplementary Figs S1 and S2, and Supplementary Table S3. All partici-
pants (and historical controls withNHL) received 19-weeks of CHOP (chemotherapy
in Supplementary Table S4) prior to T-cell infusions. PB-derived T cells were
numerically expanded over 24 to 35 days (mean 6 s.e.m. 5 30 6 2 days). PB samples
were taken at the time of enrollment, before and 3 hours after each T-cell infusion,
and continued throughout the active monitoring period. Patients were enrolled
before, during, or after CHOP. Employing an intra-patient dose escalation scheme
(Fig 3), 1 to 3 T-cell doses (up to 53107/m2, 53108/m2, and 33109/m2) were infused
based on canine body surface area (BSA)55,56. T cells were first administered at a
median of 14 days (range 7 – 448 days) after CHOP completion (Table 1). P42
relapsed prior to T-cell therapy and stable disease was achieved seven days after the
second T-cell infusion, while all other participants were in remission after CHOP and
at the time of T-cell infusions.
Control dogs. PB was obtained from healthy subjects seen at TAMU during 2010.
Size- and age- matched canines with stage IV or V biopsy-proven B-lineage NHL
treated at TAMU through the length of the T-cell trial and treated only with CHOP,
were used as matched controls for survival curves (n 5 12).
Isolation of mononuclear cells from PB. Canine-derived PB mononuclear cells
(PBMC), diluted 1510 with EDTA/PBS (Miltenyi Biotec, Auburn, CA) were isolated
by density-gradient centrifugation over Ficoll-Paque-Plus (GE Healthcare
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BioSciences, Piscataway, NJ) and cryopreserved in freeze media (FM) [10% heat-
inactivated Fetal Bovine Serum (FBS, HyClone, Logan, UT), and 10%DMSO (Sigma,
St. Louis, MO) in HyQ RPMI 1640 (HyClone)].
aAPC. The human tumor cell line K562 (homogenously expressing endogenous
CD32) was transduced with lentiviruses to co-express human CD19, CD64, CD86,
CD137L, and membrane bound human IL-15 (co-expressed with EGFP), and cloned
(Clone 4, CLN4) by limiting dilution15,57. CLN4 was fingerprinted at MDACC using
short tandem repeat PCR and proven to be derived from K562. CLN4 was c-irra-
diated (100 Gy) prior to loading with anti-human CD3 (OKT3, Muronmonab,
Orthoclone, Raritan, NJ), cryopreserved in FM and was used for propagating T cells.
Flow cytometry. Fluorochrome-conjugated monoclonal antibodies (mAbs) were
used at a 1525 dilution in flow buffer (FB) [2% FBS and 0.1% sodium azide (Sigma) in
PBS (Sigma)]: mouse anti-dog CD3 (AbD Serotec, Raleigh, NC, clone: CA17.2A12,
catalog number: MCA1774F), rat anti-dog CD4 (AbD Serotec, YKIX302.9,
MCA1038A647), rat anti-dog CD8 (AbD Serotec, YCATE55.9, MCA1039PE), and
mouse anti-dog CD21 (AbD Serotec, CA2.1D6, MCA1781PE). The following mouse
anti-human antibodies that cross-react with canine homologs were used: CD25
(Dako, Carpinteria, CA, ACT-1, F0801), CD56 (Dako, MOC-1, R7127), CCR7 (BD
Pharmingen, San Diego, CA, 3D12, 552176) and CD32 (BD Pharmingen,18.26,
559769). Cells were stained for 30 minutes at 4uC prior to washing and analysis.
Granzyme B staining was undertaken on T cells fixed for 20 minutes in BD Cytofix/
Cytoperm solution (BD Biosciences, San Jose, CA). After washing in BD perm wash
buffer, cells were incubated with mouse anti-human granzyme B (BD Pharmingen,
GB11, 560211) and isotype control (BD Pharmingen, mouse anti-Rat IgG2a, 558067)
for 30minutes. Tomeasure IFN-c expression, cells were incubatedwith golgi plug at a
151000 dilution in culture media (CM) [2 mmol/L Glutamax-1 (Life Technologies-
Invitrogen, Carlsbad, CA) and 10% heat-inactivated defined FBS inHyQRPMI 1640]
for 4 hours at 37uC before washing and fixation (as described above), and then
stained with mouse anti-bovine IFN-c mAb (AbD Serotec, CC302, MCA1783PE)
that cross-reacts with canine IFN-c. Flow cytometry confirmed expression of intro-
duced T-cell co-stimulatory molecules and the loading of OKT3 (using 15100 dilu-
tion in FB of F(ab’)2 fragment of Goat anti-Mouse IgG fragment F(ab’)2 Specific,
Jackson ImmunoResearch Laboratories, West Grove, PA, 115-116-072) on CLN4.
Data were acquired on a FACS Calibur (BD Bioscience) using Cell Quest Version 2.0
(BD Biosciences) and analyzed with FCS Express Version 3.0 (De Novo Software,
Thornhill, Ontario, Canada).
Numeric expansion of canine T cells on c-irradiated aAPC. PBMC and T cells were
cultured at 38.5uC, 5%CO2, and 96% relative humidity in CM. T cells were cultured at
a 251 (Tcell : aAPC) ratio and re-stimulated every 7–10 days with aAPC.
Recombinant human IL-21 (eBiosciences, San Diego, CA) was added (30 ng/mL)
three-times-per-week for the first seven days. Recombinant human IL-21 and rhIL-2
(Invitrogen) at 100 U/mL, was added three-times-per-week, for subsequent weekly
stimulations beginning with the re-addition of aAPC. Viable T cells were enumerated
every 7 days by Trypan blue exclusion using the Auto T4 Cell Counter Cellometer
(Nexcelom Bioscience, Lawrence, MA).
Fluorescent-labeling of propagated T cells. T cells were labeled with the red fluor-
escent dye, PKH-26, using the Cell Linker Kit for General Cell Membrane Labeling
(Sigma) based upon manufacturer’s instructions. Cells were re-suspended in Diluent
C containing 4 mL/mL of PKH-26 for 5 minutes, before adding an equal volume of
FBS. To remove unbound dye, cells were washed three times prior to use.
Direct digital detection of mRNA molecules. We generated a custom panel
(Supplementary Table S3) to quantify 346 canine genes in a single multiplexed non-
enzymatic reaction using the nCounter Prep Station and Digital Analyzer
(NanoString Technologies, Model NCT-SYST-120, Seattle, WA)58. T cells obtained
directly from PBMC were purified to homogeneity using mouse anti-canine CD3
antibody and a BD FACS Aria II high speed sorter (BD Biosciences) prior to analysis.
Expanded T cells (99% CD31 and # 1% CD321) were analyzed after 28 days of co-
culture and 7 days from the last addition of aAPC. Propagated T cells were cryo-
preserved, thawed at 37uC and rested with rhIL-2 and rhIL-21 in CM for 2 hours
before flash freezing in liquid nitrogen. Sample mRNAwas isolated using the AllPrep
DNA/RNAMini kit according tomanufacture’s instructions (Qiagen, Valencia, CA).
For the digital detection, two sequence-specific gene probes, mRNA target sequence-
specific capture probe, and a mRNA target sequence-specific fluorescent-labeled
color-coded probe were produced for each gene. 30,000 cell equivalents of each
sample were hybridized with the probe as previously described58. Data analysis and
statistical descriptions are described in the supplementary methods.
Infusion of propagated T cells. Propagated and cryopreserved autologous T-cell
products were shipped on dry ice to TAMU for infusion. T cells were thawed at 37uC
and intravenously infused within 10 minutes at a rate not exceeding 2 mL per 3
minutes. Adverse reactions were determined by the 2009 Veterinary Co-Operative
Oncology Group (VCOG) scale. Day 0 was defined as the first T-cell infusion
administered.
Complete blood counts (CBC). These were analyzed at TAMU using Abbott Cell
Dyn 3700 (Abbott Park, IL) to obtain ANC, ALC, and platelet counts.
Immunohistochemistry. Popliteal LNs were biopsied and sections snap-frozen and/
or formalin-fixed. Frozen sections were evaluated for the presence of CD3 and CD79a
using an alkaline phosphatase detection system using an autostainer (Dako), which
dispensed 300 mL of reagent per slide. Slides were either acetone or formalin-fixed for
Table 1 | Patient characteristics that received T cells after CHOP
UPN Breed Sex
Age
(yrs)
BSA
(m2)
Initial
Staging Chemotherapy
Staging at the time
of 1st T-cell infusion
No. T-cell
Infusions
No. days T cells cultured
before cryopreservation
P42 Rottweiler F 5 1.2 IV CHOP, P,M,T PD 3 35
P182 Labrador Retriever F 6 1.1 IV CHOP CR 3 35
P194 Border Collie F 6 0.9 IV CHOP CR 3 28
P200 Rottweiler M 4 1.3 V CHOP CR 3 33
P204 Labrador Retriever F 11 0.9 IV CHOP CR 3 24
P222 Cocker Spaniel F 5 0.5 IV CHOP CR 3 27
P249 Labrador Retriever F 9 1.08 IV CHOP CR 2 35
P263 Sheltie M 6 0.66 IV CHOP CR 1 35
T 5 Toceranib; M 5 MOPP; P 5 Prednisone; CR 5 Complete Remission; PD 5 Progressive Disease
The average T-cell dose for the infusions administered to 8 dogs was 6.45310861.653108 cells/m2 (mean 6 s.e.m.) (range: 53107 to 2.53109 cells/m2).
Patient P42 relapsed prior to initiation of adoptive immunotherapy and received mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), L-asparaginase, toceranib, and prednisone,
concurrent with the T-cell infusions. This dog achieved stable disease after T-cell therapy.
Table 2 | Number of canines with adverse events at least possibly attributed to T-cell infusion
Symptom
Dose1 Dose 2 Dose 3
Grade I, II Grade III, IV Grade I, II Grade III, IV Grade I, II Grade III, IV
Lethargy 0 0 0 0 0 0
Nausea 0 1 0 0 0 0
Diarrhea 0 0 2 1 0 0
Vomiting 0 0 2 1 0 0
Grading based on Veterinary Co-operative Oncology Group Scale (version 2009).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 249 | DOI: 10.1038/srep00249 10
5 minutes prior to staining. Universal Block (KPL Labs, Gaithersburg, MD) was
applied to block endogenous phosphatase. Slides were incubated for 60 minutes with
the primary antibodies diluted 15200 in Da Vinci Green Diluent (Biocare Medical,
Concord, CA): rabbit anti-human CD3 (Dako, A0452) and mouse anti-dog CD79a
(Dako, M7051, HM57). Secondary antibodies, biotinylated goat anti-mouse (KPL
Labs, 71-00-29) or goat anti-rabbit (KPL Labs, 71-00-30), were incubated for 60
minutes before streptavidin phosphatase (KPL Labs, 71-00-45). Vulcan fast red
(Biocare Medical) was used to detect the antibody binding sites. Tissues were coun-
terstained with hematoxylin (Biocare Medical).
TK measurements. 106 T cells and CLN4 were either c-irradiated at 100 Gy or
used as non-irradiated cells. Conditioned supernatants were collected from non-
irradiated T cells co-cultured for 48 hours on OKT3-loaded CLN4 with rhIL-2/rhIL-
21 in CM as well as separately from c-irradiated T cells and CLN4. TK concentration
was measured using the Liaison TK kit (310960D, DiaSorin, Stillwater, MN) in
supernatants and serum. Samples were processed according to manufacture’s
protocols on the Liaison analyzer (DiaSorin).
Statistical methods. Results for percentage and fold expansion are shown as
mean 6 standard error (s.e.m.). Further analysis used the Student’s t-test with p-
values less than 0.05 considered significant. For survival curves, Kaplan-Meier and
Log Rank analyses were completed against historical controls with p-values less than
0.05 considered statistically significant. GraphPad (GraphPad Software, San Diego,
CA) Prism version 5.0 for Windows was used for all statistical calculations.
Study was approved by the IACUC and CRRC committees at TAMU and by the
ACUF committee at MDACC.
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